In this three-part series, expert haemato-oncologists discuss MPNs, considering differences in patient and physician perceptions on the burden of disease, real-world evidence in MF, and how to change your approach based on a patient’s genetic mutations.


MF, myelofibrosis; MPN, myeloproliferative neoplasm.

HCP20-C040 August 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via uk.pa[email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]